These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21858533)

  • 1. Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001.
    Vetsika EK; Konsolakis G; Aggouraki D; Kotsakis A; Papadimitraki E; Christou S; Menez-Jamet J; Kosmatopoulos K; Georgoulias V; Mavroudis D
    Cancer Immunol Immunother; 2012 Feb; 61(2):157-168. PubMed ID: 21858533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide.
    Kotsakis A; Papadimitraki E; Vetsika EK; Aggouraki D; Dermitzaki EK; Hatzidaki D; Kentepozidis N; Mavroudis D; Georgoulias V
    Lung Cancer; 2014 Oct; 86(1):59-66. PubMed ID: 25130084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT(572Y) in cancer patients.
    Vetsika EK; Papadimitraki E; Aggouraki D; Konsolakis G; Mela ME; Kotsakis A; Christou S; Patramani S; Alefantinou M; Kaskara A; Christophyllakis C; Kosmatopoulos K; Georgoulias V; Mavroudis D
    J Immunother; 2011; 34(9):641-50. PubMed ID: 21989412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study.
    Kotsakis A; Vetsika EK; Christou S; Hatzidaki D; Vardakis N; Aggouraki D; Konsolakis G; Georgoulias V; Christophyllakis Ch; Cordopatis P; Kosmatopoulos K; Mavroudis D
    Ann Oncol; 2012 Feb; 23(2):442-9. PubMed ID: 21873272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report.
    Kjeldsen JW; Iversen TZ; Engell-Noerregaard L; Mellemgaard A; Andersen MH; Svane IM
    Front Immunol; 2018; 9():2145. PubMed ID: 30283461
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial.
    Gridelli C; Ciuleanu T; Domine M; Szczesna A; Bover I; Cobo M; Kentepozidis N; Zarogoulidis K; Kalofonos C; Kazarnowisz A; Korozan M; de Las Penas R; Majem M; Chella A; Griesinger F; Bournakis E; Sadjadian P; Kotsakis A; Chinet T; Syrigos KN; Correale P; Gallou C; Jamet JM; Vetsika EK; Kosmatopoulos K; Georgoulias V;
    Br J Cancer; 2020 May; 122(10):1461-1466. PubMed ID: 32210365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies.
    Mavroudis D; Bolonakis I; Cornet S; Myllaki G; Kanellou P; Kotsakis A; Galanis A; Nikoloudi I; Spyropoulou M; Menez J; Miconnet I; Niniraki M; Cordopatis P; Kosmatopoulos K; Georgoulias V
    Oncology; 2006; 70(4):306-14. PubMed ID: 17047402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
    Brunsvig PF; Guren TK; Nyakas M; Steinfeldt-Reisse CH; Rasch W; Kyte JA; Juul HV; Aamdal S; Gaudernack G; Inderberg EM
    Front Immunol; 2020; 11():572172. PubMed ID: 33324397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide.
    Bolonaki I; Kotsakis A; Papadimitraki E; Aggouraki D; Konsolakis G; Vagia A; Christophylakis C; Nikoloudi I; Magganas E; Galanis A; Cordopatis P; Kosmatopoulos K; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Jul; 25(19):2727-34. PubMed ID: 17602077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
    Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
    Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.
    Krug LM; Dao T; Brown AB; Maslak P; Travis W; Bekele S; Korontsvit T; Zakhaleva V; Wolchok J; Yuan J; Li H; Tyson L; Scheinberg DA
    Cancer Immunol Immunother; 2010 Oct; 59(10):1467-79. PubMed ID: 20532500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.
    Arlen P; Tsang KY; Marshall JL; Chen A; Steinberg SM; Poole D; Hand PH; Schlom J; Hamilton JM
    Cancer Immunol Immunother; 2000 Dec; 49(10):517-29. PubMed ID: 11129322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
    Brunsvig PF; Kyte JA; Kersten C; Sundstrøm S; Møller M; Nyakas M; Hansen GL; Gaudernack G; Aamdal S
    Clin Cancer Res; 2011 Nov; 17(21):6847-57. PubMed ID: 21918169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma.
    Raez LE; Cassileth PA; Schlesselman JJ; Padmanabhan S; Fisher EZ; Baldie PA; Sridhar K; Podack ER
    Cancer Gene Ther; 2003 Nov; 10(11):850-8. PubMed ID: 14605671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I Trial of Intratumoral Injection of
    Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM
    Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947
    [No Abstract]   [Full Text] [Related]  

  • 17. Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia.
    Giannopoulos K; Dmoszynska A; Kowal M; Rolinski J; Gostick E; Price DA; Greiner J; Rojewski M; Stilgenbauer S; Döhner H; Schmitt M
    Leukemia; 2010 Apr; 24(4):798-805. PubMed ID: 20220777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine.
    Dangoor A; Lorigan P; Keilholz U; Schadendorf D; Harris A; Ottensmeier C; Smyth J; Hoffmann K; Anderson R; Cripps M; Schneider J; Hawkins R
    Cancer Immunol Immunother; 2010 Jun; 59(6):863-73. PubMed ID: 20043222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response.
    Godet Y; Fabre E; Dosset M; Lamuraglia M; Levionnois E; Ravel P; Benhamouda N; Cazes A; Le Pimpec-Barthes F; Gaugler B; Langlade-Demoyen P; Pivot X; Saas P; Maillère B; Tartour E; Borg C; Adotévi O
    Clin Cancer Res; 2012 May; 18(10):2943-53. PubMed ID: 22407833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
    Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
    J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.